Here you go... I pulled this from Grows notes. It’s not my theory. It’s what the CEO said. If you follow the information about your investment you also will see and be able to know what is going on.
This is the first of three ways that Nader boasted we could get a quick EUA. Not my fantasy RTB. This is from the 13th note at 14:14 minute mark of the webinar.
13. 14:14 “First one- We can simply add more patients to the Open-Label of CD12 that we have, and recalculate the p-value until it is less than .05. Is this acceptable by regulatory agencies? I’m not sure, but we will be informing everyone about how this is shaping up. And so far, let me give you an update so you know how it is shaping up right now. Very good news today is we have 28 day mortality data amongst our new 55 patients on open arm, data, that is better in the whole mITT population and in the mITT population less than 65 or over 65 for our primary endpoint 28 day mortality. And also the results so far in that, is better in the 28 day mortality for critically ill population. And some of the results are much better. The mortality rate in the extension of CD12 right now in critically ill population is about 16.7%. About 17%. CD12 we had results of 28% in leronlimab, 37% in placebo, so the data is actually coming strong. That’s one option. Get more data. Recalculate.”
You can open Grows notes and see the other two option that could help your investment also. For me it’s just a matter of paying attention to all the options we have and following the way our investment can make us some money. To make sense of all that is said is the hard part. Paying attention to the details is even harder. Having notes like grow produces after every call/webinar is priceless.
Read More: https://investorshangout.com/post/view?id=610...z6sMXp2WLO
This is the first of three ways that Nader boasted we could get a quick EUA. Not my fantasy RTB. This is from the 13th note at 14:14 minute mark of the webinar.
13. 14:14 “First one- We can simply add more patients to the Open-Label of CD12 that we have, and recalculate the p-value until it is less than .05. Is this acceptable by regulatory agencies? I’m not sure, but we will be informing everyone about how this is shaping up. And so far, let me give you an update so you know how it is shaping up right now. Very good news today is we have 28 day mortality data amongst our new 55 patients on open arm, data, that is better in the whole mITT population and in the mITT population less than 65 or over 65 for our primary endpoint 28 day mortality. And also the results so far in that, is better in the 28 day mortality for critically ill population. And some of the results are much better. The mortality rate in the extension of CD12 right now in critically ill population is about 16.7%. About 17%. CD12 we had results of 28% in leronlimab, 37% in placebo, so the data is actually coming strong. That’s one option. Get more data. Recalculate.”
You can open Grows notes and see the other two option that could help your investment also. For me it’s just a matter of paying attention to all the options we have and following the way our investment can make us some money. To make sense of all that is said is the hard part. Paying attention to the details is even harder. Having notes like grow produces after every call/webinar is priceless.
Read More: https://investorshangout.com/post/view?id=610...z6sMXp2WLO
8
